Surgical Oncologist, Associate Professor, Clinician Investigator
Department of Surgery, University of Ottawa
Ottawa, Ontario, Canada
Dr. Carolyn Nessim is a Surgical Oncologist at the Ottawa Hospital and Associate Professor of Surgery at the University of Ottawa. She is the Program Director for the Complex Surgical Oncology Fellowship Program at the University of Ottawa. She completed her general surgery residency and master’s in biomedical sciences at the University of Montreal and did her Surgical Oncology Fellowships at the University of Toronto and the Peter MacCallum Cancer Centre in Melbourne, Australia. Her clinical practice focuses on the treatment of patients with Melanoma, Soft Tissue Sarcoma/GIST, and Gastric cancer. She is a Clinician Investigator at the Ottawa Hospital Research Institute (OHRI). She leads many collaborative research projects nationally and internationally in melanoma and soft tissue sarcoma. She is the Regional Chair of the Melanoma and Gastric Cancer Communities of Practice for Eastern Ontario and on the Cancer Care Ontario Skin Cancer Advisory Board as well the American Society of Clinical Oncology (ASCO) Melanoma Measures Panel and starting to help create Gastric Cancer Guidelines. She is the Chair of the Research Evaluation Committee of the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) and a member of the Society of Surgical Oncology (SSO) Sarcoma Disease site group. She is a topic editor for Current Oncology. She is the CPD Chair on the Board and Executive of the Canadian Association of General Surgeons (CAGS) and is also the Chair of the Surgery and Surveillance working group of the NCIC-Canadian Cancer Trials Group (CCTG). She is the President elect of the Canadian Society of Surgical Oncology (CSSO) and Education Chair and on the executive of the Canadian Gastric Cancer Association (CaGCA). She has more than 80 peer-reviewed publications and book chapters and is the local PI for international randomized clinical trials like the MELMART-2 and STRASS 2 trials at The Ottawa Hospital.
Disclosure information not submitted.
